Vascular endothelial growth factor gene polymorphisms in ovarian cancer

被引:23
作者
Polterauer, Stephan
Grimm, Christoph
Mustea, Alexander
Concin, Nicole
Tanner, Berno
Thiel, Falk
Heinze, Georg
Reinthaller, Alexander
Zeillinger, Robert
Hefler, Lukas A.
机构
[1] Med Univ Vienna, Dept Obstet & Gynecol, A-1090 Vienna, Austria
[2] Univ Med Berlin, Charite, Dept Obstet & Gynecol, Berlin, Germany
[3] Med Univ Innsbruck, Dept Obstet & Gynecol, Innsbruck, Austria
[4] Johannes Gutenberg Univ Mainz, Dept Obstet & Gynecol, D-6500 Mainz, Germany
[5] Univ Erlangen Nurnberg, Dept Obstet Gynecol, Erlangen, Germany
[6] Med Univ Vienna, Core Unit Med Stat & Informat, Vienna, Austria
[7] Ludwig Boltzmann Inst Gynecol & Gynecol Oncol, Vienna, Austria
关键词
ovarian cancer; VEGF; gene; polymorphism; prognosis;
D O I
10.1016/j.ygyno.2006.12.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Polymorphisms. within the vascular endothelial growth factor (VEGF) gene, the most important regulator of angiogenesis and vascular permeability, were shown to be independently associated with an impaired prognosis in various malignancies. No data have been reported in ovarian cancer. Methods. In the present multi-center study, we examined three common polymorphisms within the VEGF gene (VEGF +405G/C, VEGF -460C/T, and VEGF +936C/T) in 553 Caucasian patients with ovarian cancer using pyrosequencing. Results. The three investigated polymorphisms did not correlate with any of the investigated clinico-pathological parameters. In univariate and multivariate models, only FIGO stage and patient's age at diagnosis, but not any polymorphism or any haplotype were correlated with patients' overall survival. Conclusions. In our large multi-center study, the investigated VEGF gene polymorphisms were not associated with prognosis in patients with ovarian cancer. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:385 / 389
页数:5
相关论文
共 32 条
[1]  
AbuJawdeh GM, 1996, LAB INVEST, V74, P1105
[2]   Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia [J].
Banyasz, Ilona ;
Szabo, Szilvia ;
Bokodi, Geza ;
Vannay, Adam ;
Vasarhelyi, Barna ;
Szabo, Andras ;
Tulassay, Tivadar ;
Rigo, Janos, Jr. .
MOLECULAR HUMAN REPRODUCTION, 2006, 12 (04) :233-236
[3]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[4]   DNAzol(R): A reagent for the rapid isolation of genomic DNA [J].
Chomczynski, P ;
Mackey, K ;
Drews, R ;
Wilfinger, W .
BIOTECHNIQUES, 1997, 22 (03) :550-553
[5]   Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer [J].
Cohn, David E. ;
Valmadre, Sue ;
Resnick, Kimberly E. ;
Eaton, Lynne A. ;
Copeland, Larry J. ;
Fowler, Jeffrey M. .
GYNECOLOGIC ONCOLOGY, 2006, 102 (02) :134-139
[6]   p53 mutation does not affect prognosis in ovarian epithelial malignancies [J].
Fallows, S ;
Price, J ;
Atkinson, RJ ;
Johnston, PG ;
Hickey, I ;
Russell, SEH .
JOURNAL OF PATHOLOGY, 2001, 194 (01) :68-75
[7]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[8]   The biology of vascular endothelial growth factor [J].
Ferrara, N ;
DavisSmyth, T .
ENDOCRINE REVIEWS, 1997, 18 (01) :4-25
[9]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[10]   The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer [J].
Goodheart, MJ ;
Ritchie, JM ;
Rose, SL ;
Fruehauf, JP ;
De Young, BR ;
Buller, RE .
CLINICAL CANCER RESEARCH, 2005, 11 (10) :3733-3742